Firalis Molecular Precision (FMP), established in 2019 and rooted in the Firalis Group, operates as a leading Contract Research Organization (CRO) from Huningue, France.

Specialized in biomarker discovery and multi-omic analysis (genomics, proteomics, metabolomics), FMP accelerates precision medicine by improving diagnostics, understanding disease mechanisms, and evaluating drug efficacy. With advanced laboratories and a dedicated team of over 55 experts, FMP supports biotech and pharma companies globally, offering a suite of services that span pre-clinical to clinical trials, thus playing a pivotal role in advancing healthcare innovations.

Firalis Molecular Precision (FMP) is at the forefront of the multi-omics revolution bringing progress and innovation to the biopharmaceutical industry. By harnessing advanced -omics technologies and bioinformatics, they excel in identifying promising therapeutic targets and enhancing the drug development process for greater speed and reliability. Their state-of-the-art multi-omics solutions facilitate precise, high-throughput genomics, transcriptomics, and proteomics, leading to pioneering healthcare breakthroughs.

–  Therapeutic areas: Neurology, Oncology, Immunology  

–  Based in: Huningue (FRANCE) & Cambridge (USA)

–  Employees: 51 – 200

–  Created in: 2016